Targovax Pivots Towards Oncolytic Viruses
Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.
You may also be interested in...
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.